Document Detail


Carbonylation of myosin heavy chains in rat heart during diabetes.
MedLine Citation:
PMID:  20359464     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiac inotropy progressively declines during diabetes mellitus. To date, the molecular mechanisms underlying this defect remain incompletely characterized. This study tests the hypothesis that ventricular myosin heavy chains (MHC) undergo carbonylation by reactive carbonyl species (RCS) during diabetes and these modifications contribute to the inotropic decline. Male Sprague-Dawley rats were injected with streptozotocin (STZ). Fourteen days later the animals were divided into two groups: one group was treated with the RCS blocker aminoguanidine for 6 weeks, while the other group received no treatment. After 8 weeks of diabetes, cardiac ejection fraction, fractional shortening, left ventricular pressure development (+dP/dt) and myocyte shortening were decreased by 9%, 16%, 34% and 18%, respectively. Ca(2+)- and Mg(2+)-actomyosin ATPase activities and peak actomyosin syneresis were also reduced by 35%, 28%, and 72%. MHC-alpha to MHC-beta ratio was 12:88. Mass spectrometry and Western blots revealed the presence of carbonyl adducts on MHC-alpha and MHC-beta. Aminoguanidine treatment did not alter MHC composition, but it blunted formation of carbonyl adducts and decreases in actomyosin Ca(2+)-sensitive ATPase activity, syneresis, myocyte shortening, cardiac ejection fraction, fractional shortening and +dP/dt induced by diabetes. From these new data it can be concluded that in addition to isozyme switching, modification of MHC by RCS also contributes to the inotropic decline seen during diabetes.
Authors:
Chun-Hong Shao; George J Rozanski; Ryoji Nagai; Frank E Stockdale; Kaushik P Patel; Mu Wang; Jaipaul Singh; William G Mayhan; Keshore R Bidasee
Related Documents :
15270804 - Thiazolidinediones and congestive heart failure--exacerbation or new onset of left vent...
2058564 - Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the...
17083264 - Thiazolidinediones in patients with diabetes mellitus and heart failure : implications ...
1996694 - Myocardial metabolic effects of in vivo hydralazine treatment of streptozotocin-diabeti...
10424314 - The effectiveness, safety and epidemiology of the use of acarbose in the treatment of p...
19460644 - Disorders of carbohydrate or lipid metabolism in camelids.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-03-30
Journal Detail:
Title:  Biochemical pharmacology     Volume:  80     ISSN:  1873-2968     ISO Abbreviation:  Biochem. Pharmacol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-05-10     Completed Date:  2010-05-26     Revised Date:  2011-09-26    
Medline Journal Info:
Nlm Unique ID:  0101032     Medline TA:  Biochem Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  205-17     Citation Subset:  IM    
Copyright Information:
2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198-5800, United States.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Diabetes Mellitus, Experimental / metabolism*
Enzyme Inhibitors / pharmacology
Guanidines / pharmacology
Heart Diseases / metabolism*
Heart Ventricles / chemistry,  metabolism
Hemodynamics / drug effects
Male
Myocardial Contraction / drug effects,  physiology*
Myocytes, Cardiac / drug effects,  pathology,  physiology
Myosin Heavy Chains / chemistry,  metabolism*
Organometallic Compounds / chemistry,  metabolism*
Oxidative Stress
Protein Carbonylation*
Rats
Rats, Sprague-Dawley
Streptozocin
Grant Support
ID/Acronym/Agency:
AA 01128/AA/NIAAA NIH HHS; HL 090657/HL/NHLBI NIH HHS; HL-066446/HL/NHLBI NIH HHS; HL085061/HL/NHLBI NIH HHS; NS-39751/NS/NINDS NIH HHS; R01 HL085061-02/HL/NHLBI NIH HHS; R01 HL085061-03/HL/NHLBI NIH HHS; R01 HL085061-04/HL/NHLBI NIH HHS; R01 NS039751-01/NS/NINDS NIH HHS; R01 NS039751-02/NS/NINDS NIH HHS; R01 NS039751-03/NS/NINDS NIH HHS; R01 NS039751-04/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Guanidines; 0/Myosin Heavy Chains; 0/Organometallic Compounds; 18883-66-4/Streptozocin; 79-17-4/pimagedine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Involvement of natural killer T cells in halothane-induced liver injury in mice.
Next Document:  An activated renin-angiotensin system maintains normal blood pressure in aryl hydrocarbon receptor h...